Related Research Articles
Neuropsychiatry is a branch of medicine that deals with psychiatry as it relates to neurology, in an effort to understand and attribute behavior to the interaction of neurobiology and social psychology factors. Within neuropsychiatry, the mind is considered "as an emergent property of the brain", whereas other behavioral and neurological specialties might consider the two as separate entities. Those disciplines are typically practiced separately.
Guy Goodwin is a senior research fellow and until recently was the W.A. Handley Professor of Psychiatry at the University of Oxford (2014). A fellow of the Academy of Medical Sciences, Goodwin has served as principal investigator in many clinical trials for the treatment of bipolar disorder. He is also an Emeritus Senior Investigator at the National Institute for Health and Care Research (NIHR) and has been on the advisory boards of numerous research councils. He was President of the European College of Neuropsychopharmacology from 2013 to 2016.
The Semel Institute for Neuroscience and Human Behavior is a research institute of the University of California Los Angeles (UCLA). It includes a number of centers, including the "Center for Neurobehavioral Genetics", which uses DNA sequencing, gene expression studies, bioinformatics, and the genetic manipulation of model organisms to understand brain and behavioral phenotypes.
The European College of Neuropsychopharmacology (ECNP) is a pan-European, non-profit scientific association that serves as a platform to exchange and promote research in the field of neuropsychopharmacology. The ECNP “is committed to ensuring that advances in the understanding of brain function and human behaviour are translated into better treatments and enhanced public health”. The ECNP organises a number of activities to achieve this aim, such as a yearly congress, workshops, seminars, New Frontiers Meetings, publications, awards, supported talks and much more.
Barbara Jacquelyn Sahakian, is professor of clinical neuropsychology at the department of psychiatry and Medical Research Council (MRC)/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge. She is also an honorary clinical psychologist at Addenbrooke's Hospital, Cambridge. She has an international reputation in the fields of cognitive psychopharmacology, neuroethics, neuropsychology, neuropsychiatry and neuroimaging.
Joseph D. Buxbaum is an American molecular and cellular neuroscientist, autism researcher, and the Director of the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai. Buxbaum is also, along with Simon Baron-Cohen, the co-editor of the BioMed Central journal Molecular Autism, and is a member of the scientific advisory board of the Autism Science Foundation. Buxbaum is a Professor of Psychiatry, Neuroscience, and Genetics and Genomic Sciences. He is also the Vice Chair for Research and for Mentoring in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai.
Eduard Vieta Pascual is a Catalan psychiatrist from Spain known for his work in the field of mood disorders. His unit is a world reference in clinical care, research and teaching of bipolar disorder and depression.
Mark J. Millan is a neuroscientist specialising in the study and improved treatment of disorders of brain. He was the Director of Pharmacological Innovation for the Central Nervous System (CNS) at the Institut de Recherché de Servier (IDRS) in Paris, France. He also served as the Secretary of the European College of Neuropsychopharmacology. Currently he is a Visiting Professor in the School of Psychology and Neuroscience at the University of Glasgow. Born in Edinburgh, he is the son of former Scottish Labour Party Leader and European Commissioner, Bruce Millan. He studied at Cambridge University and then spent ten years at the Max Planck Institute of Psychiatry, Munich, before moving to Paris.
Wim van den Brink is emeritus Professor of Psychiatry and Addiction at the Academic Medical Center, University of Amsterdam. He was Director of the Amsterdam Institute for Addiction Research (AIAR) and Scientific Director of the National Committee for Treatment of Heroin Addiction (CCBH) in Utrecht, the Netherlands.
Joseph Zohar is the director of Psychiatry and the Anxiety and Obsessive Compulsive Clinic at the Sheba Medical Center in Tel HaShomer and professor of psychiatry at Tel Aviv University, Israel. He is the founder of the World Council on Anxiety as well as the Israeli Consortium on PTSD. He currently leads the chief installation of the Israeli Defense Force for the treatment of PTSD. He was a longtime member of the executive committee of the European College of Neuropsychopharmacology, of which he is a former president, and chairman of the Expert Platform on Mental Health.
Elisabeth Binder is a medical doctor and neuroscientist specializing in the study of mood and anxiety disorders. She is the director of the Department of Translational Research of the Max Planck Institute of Psychiatry in Munich, Germany. In addition to research, she serves as Vice-President of the European College of Neuropsychopharmacology (ECNP) and is a member of the Executive Committee.
Charles L. Raison is an American psychiatrist and professor of psychiatry at the University of Wisconsin-Madison School of Medicine and Public Health as well as the Mary Sue and Mike Shannon Chair for Healthy Minds, Children & Families and Professor with the School of Human Ecology in Madison, Wisconsin.
Prof. Robert Haim Belmaker, is an Israeli psychiatrist who has had major academic positions in Israeli psychiatry since 1974. He had a formative influence on biological directions in Israeli psychiatry. He was Hoffer-Vickar Professor of Psychiatry at Ben-Gurion University of the Negev, Beersheva Israel until his retirement and is now Emeritus.
Joseph Thomas Coyle Jr. is an American psychiatrist and neuroscientist. He is the Eben S. Draper Professor of Psychiatry and Neuroscience at Harvard Medical School.
Lisa M. Monteggia is an American neuroscientist who is a Professor in the Department of Pharmacology, Psychiatry & Psychology as well as the Barlow Family Director of the Vanderbilt Brain Institute at Vanderbilt University in Nashville, Tennessee. Monteggia probes the molecular mechanisms underlying psychiatric disorders and has made critical discoveries about the role of the neurotrophins in antidepressant efficacy, the antidepressant mechanisms of Ketamine, as well as the epigenetic regulation of synaptic transmission by MeCP2.
Christopher J. Pittenger is an American psychiatrist and translational neuroscientist. He is a professor of psychiatry at the Yale School of Medicine and Director of the Yale OCD Research Clinic.
Gabriella Gobbi is an Italo-Canadian psychiatrist and neuroscientist whose research explores novel treatments for mental health disorders. Gobbi is a professor at McGill University's Department of Psychiatry and a Canada Research Chair in Therapeutics for Mental Health.
Andreas Reif is a German psychiatrist. He is director of the Clinic for Psychiatry, Psychosomatics and Psychotherapy at the University Hospital Frankfurt.
David S. Baldwin, MA, DM, FRCPsych, FRSA, FHEA is a British psychiatrist and academic, currently serving as professor of psychiatry in the Faculty of Medicine at the University of Southampton, UK. His research focuses on neurobiological and psychological factors in mood and anxiety disorders, aiming to improve treatment outcomes through innovative clinical approaches and trial design.
Paolo Brambilla, MD, PhD is an Italian medical doctor, child and adult psychiatrist, psychotherapist, and psychoanalyst in training. He is recognized for his contributions to psychiatry and neuroscience, particularly in mood and anxiety disorders, schizophrenia, developmental psychopathology, and neuroimaging.
References
| International | |
|---|---|
| National | |
